Clinical Trials Browser

INDUSTRY × asciminib × 90 days × Clear all

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03874858 2026-04-02

DANTE

Phase 2 Completed

124 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07354074 2026-03-23

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase 2 Not yet recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

568 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-02-06

ASSURE-3

Active not recruiting

201 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Phase 1/2 Not yet recruiting

50 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

ASC4INDIA

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

DANTE

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Asciminib Roll-over Study

ASC4START

ASSURE-3

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)